PALO ALTO, Calif.--(BUSINESS WIRE)--KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced that the company has begun dosing subjects in a U.S. Phase 1 study of its second drug candidate, KB001, in healthy volunteers. KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients.
